Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Revenues, net (Tables)

Revenues, net (Tables)

9 Months Ended

Sep. 30, 2025

Revenue From Contract With Customer [Abstract]

Summary of revenues disaggregated by category

Revenues, net by category were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Endari® - US	$	2,122	$	2,757	$	6,500	$	10,575
Endari® - International		1,234		2,485		1,906		2,362
Other		22		236		195		424
Revenues, net		3,378		5,478		8,601		13,361

Revenue Allowance and Accrual Activities

The following table summarizes the revenue allowance and accrual activities for the nine months ended September 30, 2025 and September 30, 2024 (in thousands):


	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns			Total
Balance as of January 1, 2025	$	1,135		$	6,812		$	138		$	8,085
Provision related to sales in the current year		589			2,306			81			2,976
Adjustments related to prior period sales		(2	)		32			—			30
Credits and payments made		(741	)		(1,349	)		(70	)		(2,160	)
Balance as of September 30, 2025	$	981		$	7,801		$	149		$	8,931

Balance as of January 1, 2024	$	1,212		$	5,658		$	863		$	7,733
Provision related to sales in the current year		939			2,530			114			3,583
Adjustments related to prior period sales		(79	)		34			47			2
Credits and payments made		(1,175	)		(1,683	)		(913	)		(3,771	)
Balance as of September 30, 2024	$	897		$	6,539		$	111		$	7,547

Summarizes revenues from each of our customers accounted for 10% or more of net revenues

The following table summarizes revenues attributable to each of the customers that accounted for 10% or more of our net revenues in any of the periods shown:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Customer A		9	%		4	%		13	%		25	%
Customer B		12	%		6	%		12	%		20	%
Customer C		14	%		11	%		15	%		6	%
Customer D		21	%		20	%		25	%		17	%
Customer E	<1%				27	%	<1%				11	%